Zhitong Finance App News, Enhua Pharmaceutical (002262.SZ) issued an announcement. The company recently received the “Drug Clinical Trial Approval Notice” for the Class 1 chemical NH130 citrate tablets approved and issued by the State Drug Administration, and will conduct clinical trials in the near future. NH130 citrate is a potent 5-HT2A receptor reverse agonist. Preclinical trial results show that NH130 citrate is effective in animal models of schizophrenia and ADP without affecting motor function. At the same time, adverse reactions such as cardiotoxicity and phospholipid deposition are small, the safety window is large, and it has good pharmacological characteristics.

Zhitong Finance App News, Enhua Pharmaceutical (002262.SZ) issued an announcement. The company recently received the “Drug Clinical Trial Approval Notice” for the Class 1 chemical NH130 citrate tablets approved and issued by the State Drug Administration, and will conduct clinical trials in the near future. NH130 citrate is a potent 5-HT2A receptor reverse agonist. Preclinical trial results show that NH130 citrate is effective in animal models of schizophrenia and ADP without affecting motor function. At the same time, adverse reactions such as cardiotoxicity and phospholipid deposition are small, the safety window is large, and it has good pharmacological characteristics.